<p>隨着美國股市面臨挑戰，主要指數出現周度虧損，國債收益率達到四個月來的最高點，投資者正在密切關注各個行業的潛在機會。便士股票通常與較小或較新的公司相關，對於那些尋求主流市場巨頭之外的增長前景的投資者來説，仍然是一個引人注目的領域。儘管今天被認為有些小眾，但便士股票在財務健康和行業內戰略定位良好的情況下，仍然可以提供顯著的潛力。</p>
<h3>美國十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.61</td>
<td>$559.34M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.79</td>
<td>$647.38M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.825</td>
<td>$141.09M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.00</td>
<td>$504.79M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.25</td>
<td>$1.36B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$614.03M</td>
<td>✅ 5 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.31</td>
<td>$912.62M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.91</td>
<td>$6.61M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.90</td>
<td>$88.36M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國便士股票篩選器的 334 只股票完整列表。</p>
<p>讓我們回顧一些我們篩選出的顯著股票。</p>
<h2>ATA Creativity Global (AACG)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> ATA Creativity Global 及其子公司在中國和國際上提供教育服務，市值為 3684 萬美元。</p>
<p><strong>運營：</strong> 公司的收入部分包括來自細分調整的人民幣 2.5691 億元和其他教育服務的人民幣 2299 萬元。</p>
<p><strong>市值：</strong> $36.84M</p>
<p>ATA Creativity Global 市值為 3684 萬美元，儘管尚未盈利，但其財務狀況有所改善。公司在過去一年中顯著減少了淨虧損，並在 2025 年第三季度報告了人民幣 237 萬元的淨收入，而之前則是淨虧損。其短期資產超過長期負債，但不足以覆蓋短期負債，突顯出潛在的流動性問題。最近通過股權發行籌集 885 萬美元的努力表明其持續的資本需求。儘管管理層和董事會經驗豐富，但該股票仍然高度波動，周度波動率從 18% 降至 12%。</p>
<ul>
<li>點擊這裏訪問我們的完整財務健康分析報告，以瞭解 ATA Creativity Global 的動態。</li>
<li>通過查看我們的業績歷史報告，瞭解 ATA Creativity Global 的表現記錄。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/72e41983-3668-429b-8c7c-04ae55a7571c/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/72e41983-3668-429b-8c7c-04ae55a7571c/chart/debt-equity-history-analysis"/></p>
<p>AACG 債務與股本歷史及分析截至 2026 年 1 月</p>
<h2>Aldeyra Therapeutics (ALDX)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Aldeyra Therapeutics, Inc.是一家生物技術公司，專注於發現和開發針對免疫介導和代謝疾病的療法，市值約為 2.7855 億美元。</p>
<p><strong>運營：</strong> Aldeyra Therapeutics, Inc.尚未報告任何收入部分。</p>
<p><strong>市值：</strong> $278.55M</p>
<p>Aldeyra Therapeutics 市值為 2.7855 億美元，尚未產生收入且仍處於虧損狀態，但在過去五年中已成功減少虧損。公司最近因額外數據請求而面臨 FDA 對其 reproxalap NDA 的延期，但未收到該機構的重大缺陷。Aldeyra 的現金狀況超過其總債務，為其運營提供了一年以上的充足資金。儘管股價波動性高且股本回報率為負，Aldeyra 經驗豐富的管理層和董事會為其在免疫介導療法的進展提供了穩定性。</p>
<ul>
<li>通過閲讀我們的資產負債表健康報告，深入瞭解 Aldeyra Therapeutics 的表現。</li>
<li>在這裏瞭解 Aldeyra Therapeutics 的未來增長軌跡。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55e4738e-9ff5-4d4f-8334-fd9b51fc6541/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55e4738e-9ff5-4d4f-8334-fd9b51fc6541/chart/debt-equity-history-analysis"/></p>
<p>ALDX 債務與股本歷史及分析截至 2026 年 1 月</p>
<h2>MediciNova (MNOV)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> MediciNova, Inc.是一家生物製藥公司，開發針對美國嚴重疾病的創新小分子治療藥物，市值為 7863 萬美元。</p>
<p><strong>運營：</strong> MediciNova, Inc.未報告任何收入部分。</p>
<p><strong>市值：</strong> $78.63M</p>
<p>MediciNova 市值為 7863 萬美元，尚未產生收入且處於虧損狀態，但在過去五年中已減少虧損。公司最近完成了其第二階段 OXTOX 研究和第二階段/第三階段 COMBAT-ALS 試驗的患者招募，均使用 MN-166（ibudilast），該藥物已獲得 FDA 和 EMA 的孤兒藥資格。儘管股價波動性高，MediciNova 經驗豐富的管理團隊為其在神經退行性疾病領域的管線推進提供了穩定性。最近進行的 5000 萬美元后續股權發行旨在增強其在持續臨牀開發中的財務資源。</p>
<ul>
<li>通過我們的全面資產負債表健康報告，深入瞭解 MediciNova 的複雜性。</li>
<li>通過我們的詳細增長報告評估 MediciNova 的未來收益預期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7e64759a-aaa7-429b-bb54-bf40a8c048cc/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7e64759a-aaa7-429b-bb54-bf40a8c048cc/chart/financial-position-analysis"/></p>
<p>MNOV 財務狀況分析截至 2026 年 1 月</p>
<h2>利用機會</h2>
<ul>
<li>在這裏開始您的投資之旅，瞭解我們精選的 334 只美國便士股票。</li>
<li>想探索一些替代方案嗎？尋找那些現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>

Aldeyra治療

美第奇新星生物技術

AACG

<p>ATA Creativity Global 被認為是在美國股市面臨挑戰的情況下，三隻有前景的低價股之一。該公司的市值為 3684 萬美元，提供教育服務，並且財務狀況有所改善，淨虧損顯著減少。儘管存在流動性擔憂，但它通過股權融資籌集了 885 萬美元。該股票仍然波動，但周波動性有所下降。其他值得注意的低價股包括 Aldeyra Therapeutics 和 MediciNova，均屬於生物技術領域，專注於滿足醫療需求的治療方案，儘管尚未盈利，但顯示出增長潛力</p>

<p>As the U.S. stock market faces a challenging period with major indexes posting weekly losses and Treasury yields reaching a four-month high, investors are keenly observing potential opportunities in various sectors. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking growth prospects outside of the mainstream market giants. Despite being considered somewhat niche today, penny stocks can still offer significant potential when backed by robust financial health and strategic positioning within their industries.</p>
<div class="lb-trans"><p>隨着美國股市面臨挑戰，主要指數出現周度虧損，國債收益率達到四個月來的最高點，投資者正在密切關注各個行業的潛在機會。便士股票通常與較小或較新的公司相關，對於那些尋求主流市場巨頭之外的增長前景的投資者來説，仍然是一個引人注目的領域。儘管今天被認為有些小眾，但便士股票在財務健康和行業內戰略定位良好的情況下，仍然可以提供顯著的潛力。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美國十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.61</td>
<td>$559.34M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.79</td>
<td>$647.38M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.825</td>
<td>$141.09M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.00</td>
<td>$504.79M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.25</td>
<td>$1.36B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$614.03M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.31</td>
<td>$912.62M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.91</td>
<td>$6.61M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.90</td>
<td>$88.36M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.61</td>
<td>$559.34M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.79</td>
<td>$647.38M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.825</td>
<td>$141.09M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.00</td>
<td>$504.79M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.25</td>
<td>$1.36B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$614.03M</td>
<td>✅ 5 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.31</td>
<td>$912.62M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.91</td>
<td>$6.61M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.90</td>
<td>$88.36M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 334 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國便士股票篩選器的 334 只股票完整列表。</p>
</div><p>Let's review some notable picks from our screened stocks.</p>
<div class="lb-trans"><p>讓我們回顧一些我們篩選出的顯著股票。</p>
</div><h2>ATA Creativity Global (AACG)</h2>
<div class="lb-trans"><h2>ATA Creativity Global (AACG)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> ATA Creativity Global, along with its subsidiaries, offers educational services both in China and internationally, with a market cap of $36.84 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> ATA Creativity Global 及其子公司在中國和國際上提供教育服務，市值為 3684 萬美元。</p>
</div><p><strong>Operations:</strong> The company's revenue segments include CN¥256.91 million from Segment Adjustment and CN¥22.99 million from Other Educational Services.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入部分包括來自細分調整的人民幣 2.5691 億元和其他教育服務的人民幣 2299 萬元。</p>
</div><p><strong>Market Cap:</strong> $36.84M</p>
<div class="lb-trans"><p><strong>市值：</strong> $36.84M</p>
</div><p>ATA Creativity Global, with a market cap of $36.84 million, has shown improvement in its financials despite being unprofitable. The company reduced its net loss significantly over the past year and reported a net income of CN¥2.37 million for Q3 2025, compared to a net loss previously. Its short-term assets exceed long-term liabilities but fall short against short-term liabilities, highlighting potential liquidity concerns. Recent efforts to raise $8.85 million through equity offerings suggest ongoing capital needs. While the management and board are seasoned, the stock remains highly volatile with decreased weekly volatility from 18% to 12%.</p>
<div class="lb-trans"><p>ATA Creativity Global 市值為 3684 萬美元，儘管尚未盈利，但其財務狀況有所改善。公司在過去一年中顯著減少了淨虧損，並在 2025 年第三季度報告了人民幣 237 萬元的淨收入，而之前則是淨虧損。其短期資產超過長期負債，但不足以覆蓋短期負債，突顯出潛在的流動性問題。最近通過股權發行籌集 885 萬美元的努力表明其持續的資本需求。儘管管理層和董事會經驗豐富，但該股票仍然高度波動，周度波動率從 18% 降至 12%。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of ATA Creativity Global.</li>
<li>Understand ATA Creativity Global's track record by examining our performance history report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整財務健康分析報告，以瞭解 ATA Creativity Global 的動態。</li>
<li>通過查看我們的業績歷史報告，瞭解 ATA Creativity Global 的表現記錄。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/72e41983-3668-429b-8c7c-04ae55a7571c/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/72e41983-3668-429b-8c7c-04ae55a7571c/chart/debt-equity-history-analysis"/></p>
<p>AACG Debt to Equity History and Analysis as at Jan 2026</p>
<div class="lb-trans"><p>AACG 債務與股本歷史及分析截至 2026 年 1 月</p>
</div><h2>Aldeyra Therapeutics (ALDX)</h2>
<div class="lb-trans"><h2>Aldeyra Therapeutics (ALDX)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated and metabolic diseases, with a market cap of approximately $278.55 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Aldeyra Therapeutics, Inc.是一家生物技術公司，專注於發現和開發針對免疫介導和代謝疾病的療法，市值約為 2.7855 億美元。</p>
</div><p><strong>Operations:</strong> Aldeyra Therapeutics, Inc. has not reported any revenue segments.</p>
<div class="lb-trans"><p><strong>運營：</strong> Aldeyra Therapeutics, Inc.尚未報告任何收入部分。</p>
</div><p><strong>Market Cap:</strong> $278.55M</p>
<div class="lb-trans"><p><strong>市值：</strong> $278.55M</p>
</div><p>Aldeyra Therapeutics, with a market cap of US$278.55 million, is pre-revenue and remains unprofitable, yet it has managed to reduce its losses over the past five years. The company recently faced an FDA extension for its reproxalap NDA due to additional data requests but received no major deficiencies from the agency. Aldeyra's cash position exceeds its total debt, providing a sufficient runway for operations beyond a year. Despite high share price volatility and negative return on equity, Aldeyra's seasoned management and board offer stability as it pursues advancements in immune-mediated therapies.</p>
<div class="lb-trans"><p>Aldeyra Therapeutics 市值為 2.7855 億美元，尚未產生收入且仍處於虧損狀態，但在過去五年中已成功減少虧損。公司最近因額外數據請求而面臨 FDA 對其 reproxalap NDA 的延期，但未收到該機構的重大缺陷。Aldeyra 的現金狀況超過其總債務，為其運營提供了一年以上的充足資金。儘管股價波動性高且股本回報率為負，Aldeyra 經驗豐富的管理層和董事會為其在免疫介導療法的進展提供了穩定性。</p>
</div><ul>
<li>Get an in-depth perspective on Aldeyra Therapeutics' performance by reading our balance sheet health report here.</li>
<li>Learn about Aldeyra Therapeutics' future growth trajectory here.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的資產負債表健康報告，深入瞭解 Aldeyra Therapeutics 的表現。</li>
<li>在這裏瞭解 Aldeyra Therapeutics 的未來增長軌跡。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55e4738e-9ff5-4d4f-8334-fd9b51fc6541/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/55e4738e-9ff5-4d4f-8334-fd9b51fc6541/chart/debt-equity-history-analysis"/></p>
<p>ALDX Debt to Equity History and Analysis as at Jan 2026</p>
<div class="lb-trans"><p>ALDX 債務與股本歷史及分析截至 2026 年 1 月</p>
</div><h2>MediciNova (MNOV)</h2>
<div class="lb-trans"><h2>MediciNova (MNOV)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> MediciNova, Inc. is a biopharmaceutical company that develops novel small molecule therapeutics for serious diseases with unmet medical needs in the United States, with a market cap of $78.63 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> MediciNova, Inc.是一家生物製藥公司，開發針對美國嚴重疾病的創新小分子治療藥物，市值為 7863 萬美元。</p>
</div><p><strong>Operations:</strong> MediciNova, Inc. does not report any revenue segments.</p>
<div class="lb-trans"><p><strong>運營：</strong> MediciNova, Inc.未報告任何收入部分。</p>
</div><p><strong>Market Cap:</strong> $78.63M</p>
<div class="lb-trans"><p><strong>市值：</strong> $78.63M</p>
</div><p>MediciNova, with a market cap of US$78.63 million, is pre-revenue and unprofitable but has reduced losses over the past five years. The company recently completed patient enrollment for its Phase 2 OXTOX study and Phase 2b/3 COMBAT-ALS trial, both utilizing MN-166 (ibudilast), which has Orphan Drug Designation from the FDA and EMA. Despite high share price volatility, MediciNova's seasoned management team provides stability as it advances its pipeline in neurodegenerative diseases. A recent follow-on equity offering of US$50 million aims to bolster financial resources amid ongoing clinical developments.</p>
<div class="lb-trans"><p>MediciNova 市值為 7863 萬美元，尚未產生收入且處於虧損狀態，但在過去五年中已減少虧損。公司最近完成了其第二階段 OXTOX 研究和第二階段/第三階段 COMBAT-ALS 試驗的患者招募，均使用 MN-166（ibudilast），該藥物已獲得 FDA 和 EMA 的孤兒藥資格。儘管股價波動性高，MediciNova 經驗豐富的管理團隊為其在神經退行性疾病領域的管線推進提供了穩定性。最近進行的 5000 萬美元后續股權發行旨在增強其在持續臨牀開發中的財務資源。</p>
</div><ul>
<li>Navigate through the intricacies of MediciNova with our comprehensive balance sheet health report here.</li>
<li>Assess MediciNova's future earnings estimates with our detailed growth reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的全面資產負債表健康報告，深入瞭解 MediciNova 的複雜性。</li>
<li>通過我們的詳細增長報告評估 MediciNova 的未來收益預期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7e64759a-aaa7-429b-bb54-bf40a8c048cc/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/7e64759a-aaa7-429b-bb54-bf40a8c048cc/chart/financial-position-analysis"/></p>
<p>MNOV Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>MNOV 財務狀況分析截至 2026 年 1 月</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用機會</h2>
</div><ul>
<li>Embark on your investment journey to our 334 US Penny Stocks selection here.</li>
<li>Want To Explore Some Alternatives? Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏開始您的投資之旅，瞭解我們精選的 334 只美國便士股票。</li>
<li>想探索一些替代方案嗎？尋找那些現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div>

ATA Creativity Global 位列三隻有潛力的便士股之中